A carregar...
Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia
Fludarabine, cyclophosphamide, and rituximab (FCR) has represented a significant treatment advancement in chronic lymphocytic leukemia (CLL). In the new scenario of targeted agents, there is an increasing interest in identifying patients who gain the maximum benefit from FCR. In this observational m...
Na minha lista:
| Publicado no: | Blood |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Society of Hematology
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4743433/ https://ncbi.nlm.nih.gov/pubmed/26276669 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2015-05-647925 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|